Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

@article{Egan2004ImmunogenicityOA,
  title={Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.},
  author={Michael A. Egan and Siew Yen Chong and Nina F. Rose and Shakuntala Megati and Kevin J Lopez and Eva B Schadeck and John E. Johnson and Amjed Masood and Priscilla Piacente and Robert E Druilhet and Paul W Barras and Dana L. Hasselschwert and Patricia Reilly and Eric M. Mishkin and David C. Montefiori and Mark G. Lewis and David K. Clarke and R. Michael Hendry and Preston A Marx and John H. Eldridge and Stephen A. Udem and Zimra R Israel and John K. Rose},
  journal={AIDS research and human retroviruses},
  year={2004},
  volume={20 9},
  pages={989-1004}
}
An experimental AIDS vaccine based on attenuated, recombinant vesicular stomatitis virus (rVSV), when administered by a combination of parenteral and mucosal routes, has proven effective at preventing AIDS in a rhesus macaque model (Rose NF, et al.: Cell 2001;106:539-549). In an effort to determine the optimal route of vaccine administration we evaluated the ability of rVSV-based vaccine vectors expressing HIV-1 Env and SIV Gag proteins, when given either intramuscularly (i.m.) or intranasally… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…